Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 8/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359653 | 0.86 | LMNA (0.41) | DCTPP1LMNAALDH1A1TLR7AR | |
| SCHEMBL17357998 | 0.81 | DCTPP1 (0.47) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358035 | 0.80 | DCTPP1 (0.49) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358001 | 0.79 | LMNA (0.44) | DCTPP1LMNAALDH1A1GAATLR7 | |
| SCHEMBL17358068 | 0.77 | PTGS1 (0.41) | DCTPP1LMNAALDH1A1SMN1; SMN2TLR7 | |
| SCHEMBL17358010 | 0.76 | DCTPP1 (0.52) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358072 | 0.75 | DCTPP1 (0.48) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358015 | 0.75 | DCTPP1 (0.48) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358014 | 0.74 | DCTPP1 (0.48) | DCTPP1CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL17358034 | 0.72 | LMNA (0.43) | CHRNB2CHRNA4LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963451-B2 | Fused ring pyrimidine compound and pest control agent containing the same | MITSUI CHEMICALS AGRO, INC. (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20150368249-A1 | FUSED RING PYRIMIDINE COMPOUND AND PEST CONTROL AGENT CONTAINING THE SAME | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368249-A1 | FUSED RING PYRIMIDINE COMPOUND AND PEST CONTROL AGENT CONTAINING THE SAME | CBR3, HRH2, HRH4 | DCTPP1 2706/4885CHRNB2 2702/4885CHRNA4 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.